Abstract
Vascular disorders, resulting from endothelial cell dysfunction, may be caused by various stimuli, including infectious pathogens, cytotoxic reagents, and pathophysiological mechanisms mediated by immune responses. Endothelial cell dysfunction characterized by apoptosis and abnormal immune activation is, at least in part, induced by antiendothelial cell antibody (AECA) in some cases of autoimmune disease. However, the molecular mechanisms of AECAmediated pathogenetic damage to host vascular system remain unclear. The dual role of nitric oxide (NO) both in endothelial cell apoptosis and survival has been described. In this paper, endothelial cell apoptosis caused by the presence of cross-reactive AECA via a NO-mediated mechanism is demonstrated in dengue virus infection. Endothelial cells undergo apoptosis via the mitochondria-dependent pathway that is regulated by NO production. NO-regulated endothelial cell injury thus may play a role in the disruption of vessel endothelium and contribute to the AECA-induced pathogenesis of vasculopathy. The modulation of NO may provide the therapeutic strategies for autoimmune diseases by preventing the AECA-mediated endothelial cell damage.
Keywords: anti-endothelial cell antibody, apoptosis, nitric oxide
Current Pharmaceutical Design
Title: Antibody-Mediated Endothelial Cell Damage Via Nitric Oxide
Volume: 10 Issue: 2
Author(s): Y. S. Lin, C. F. Lin, H. Y. Lei, H. S. Liu, T. M. Yeh, S. H. Chen and C. C. Liu
Affiliation:
Keywords: anti-endothelial cell antibody, apoptosis, nitric oxide
Abstract: Vascular disorders, resulting from endothelial cell dysfunction, may be caused by various stimuli, including infectious pathogens, cytotoxic reagents, and pathophysiological mechanisms mediated by immune responses. Endothelial cell dysfunction characterized by apoptosis and abnormal immune activation is, at least in part, induced by antiendothelial cell antibody (AECA) in some cases of autoimmune disease. However, the molecular mechanisms of AECAmediated pathogenetic damage to host vascular system remain unclear. The dual role of nitric oxide (NO) both in endothelial cell apoptosis and survival has been described. In this paper, endothelial cell apoptosis caused by the presence of cross-reactive AECA via a NO-mediated mechanism is demonstrated in dengue virus infection. Endothelial cells undergo apoptosis via the mitochondria-dependent pathway that is regulated by NO production. NO-regulated endothelial cell injury thus may play a role in the disruption of vessel endothelium and contribute to the AECA-induced pathogenesis of vasculopathy. The modulation of NO may provide the therapeutic strategies for autoimmune diseases by preventing the AECA-mediated endothelial cell damage.
Export Options
About this article
Cite this article as:
Lin S. Y., Lin F. C., Lei Y. H., Liu S. H., Yeh M. T., Chen H. S. and Liu C. C., Antibody-Mediated Endothelial Cell Damage Via Nitric Oxide, Current Pharmaceutical Design 2004; 10 (2) . https://dx.doi.org/10.2174/1381612043453469
DOI https://dx.doi.org/10.2174/1381612043453469 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gene Therapy Using IL-12 Family Members in Infection, Auto-Immunity, and Cancer
Current Gene Therapy Therapeutic Use of Vitamin D and its Analogues in Autoimmunity
Recent Patents on Inflammation & Allergy Drug Discovery Central Self - Tolerance by Thymic Presentation of Self - Antigens and Autoimmunity
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Role of the Immune System in Autism Spectrum Disorders (ASD)
CNS & Neurological Disorders - Drug Targets Mucosal Healing in Ulcerative Colitis: Where do we Stand?
Current Drug Targets Potassium Channel Blockade by the Sea Anemone Toxin ShK for the Treatment of Multiple Sclerosis and Other Autoimmune Diseases
Current Medicinal Chemistry Anti-TNF-α Antibody Therapies in Autoimmune Diseases
Current Topics in Medicinal Chemistry Current and Potential Agents for the Treatment of Alopecia Areata
Current Pharmaceutical Design NF-κB in Type 1 Diabetes
Inflammation & Allergy - Drug Targets (Discontinued) Pharmacological Targeting of IDO-Mediated Tolerance for Treating Autoimmune Disease
Current Drug Metabolism Monocyte Dependent Regulation of Autoimmune Inflammation
Current Molecular Medicine Role of Glucocorticoids in Breast Cancer
Current Pharmaceutical Design Emerging Treatment Strategies and Potential Therapeutic Targets in Primary Sjogrens Syndrome
Inflammation & Allergy - Drug Targets (Discontinued) Fc Engineering to Improve the Function of Therapeutic Antibodies
Current Pharmaceutical Biotechnology Leptin, Immune Responses and Autoimmune Disease. Perspectives on the Use of Leptin Antagonists
Current Pharmaceutical Design Recent Patents on Immunoregulatory DNA Vaccines for Autoimmune Diseases and Allograft Rejection
Recent Patents on DNA & Gene Sequences Mediators of Tyrosine Phosphorylation in Innate Immunity: From Host Defense to Inflammation onto Oncogenesis
Current Signal Transduction Therapy Effect of Recombinant Human Thymosin-α1, an Immuno-Modulating Peptide with 28 Amino Acids, on the Activity of Cytochrome P450s
Drug Metabolism Letters Exploring the Role of Nerve Growth Factor in Multiple Sclerosis: Implications in Myelin Repair
CNS & Neurological Disorders - Drug Targets Scorpion Toxin Polyptides as Therapeutic Agents: An Overview
Protein & Peptide Letters